STOK
Stoke Therapeutics, Inc.
$31.38
-1.45 (-4.42%)
At close · Jul 10
Market Cap
$1.95B
Shares
62,281,655
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$31.38
Open$32.83
Day$30.07–33.02
52W$11.66–40.22
Avg vol 30d886K
Short int13.9M · 22.3% float · 10.0d
Short vol56%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 15, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
+1%
above
RSI (14)
49
neutral
MACD trend
Positive
52-week position
69%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+7%
trailing
YTD return
−1%
this year
Relative strength
−2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $31 › 200d $31 — 200d above 50d
Institutional flow
Accumulating
7 of 196 funds reported for Jun 30 · net +249.4K sh shares · +1 new
Insider flow
Distributing
Net -$128.4K over 90 days · 100% sells
Short interest
Rising
22.33% of float · ▲ +18.7% MoM · 10.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
196 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+405%
Y/Y
EPS growth
+93%
Y/Y
Free cash flow
$44.9M
Balance sheet
$84.2M
net cash
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
+1%
Bullish
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
69%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
Death cross
50d $31 › 200d $31 — 200d above 50d
Institutional flow
Accumulating
7 of 196 funds reported for Jun 30 · net +249.4K sh shares · +1 new
Insider flow
Distributing
Net -$128.4K over 90 days · 100% sells
Short interest
Rising
22.33% of float · ▲ +18.7% MoM · 10.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
196 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $12
Now $31 · 69%
52-wk high $40
vs 200-day avg 0%
vs 50-day avg +1%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| doses administered in Phase 1/2a and ongoing OLE studies | 850 | Q1 FY2026 | — |
| elevated CSF protein lab values occurrence in patients | 94% | Q1 FY2026 | — |
| patients randomized to zorevunersen or sham | 130 | Q1 FY2026 | — |
| Phase 1 OSPREY study sites | 7 | Q1 FY2026 | — |
| planned enrollment in Phase 3 EMPEROR study | 150 | Q1 FY2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STOK
this stock
Stoke Therapeutics, Inc.
|
$1.95B | -1.1% | +404.5% | — | 22.3% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STOK | -4.0% | +10.2% | +7.2% | -4.1% | -1.1% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -5.4% | +6.1% | -1.9% | -5.2% | -11.8% |